| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1600-6143.2012.03995.X |
| P698 | PubMed publication ID | 22420671 |
| P50 | author | Julie K Heimbach | Q91078860 |
| P2093 | author name string | M D Stegall | |
| M J Gandhi | |||
| T Taner | |||
| S O Sanderson | |||
| C R Poterucha | |||
| S R De Goey | |||
| P433 | issue | 6 | |
| P304 | page(s) | 1504-1510 | |
| P577 | publication date | 2012-03-15 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year | |
| P478 | volume | 12 |
| Q39630785 | 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody |
| Q88670772 | A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients |
| Q33422561 | ABO-compatible liver allograft antibody-mediated rejection: an update |
| Q35546323 | Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features |
| Q37380304 | Anti-HLA and anti-MICA antibodies in liver transplant recipients: effect on long-term graft survival |
| Q36216606 | Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss |
| Q92243559 | Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver-kidney transplant recipients |
| Q26780271 | Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation |
| Q33742366 | Combined heart-liver transplantation: Indications, outcomes and current experience |
| Q88663316 | Contemporary Strategies and Barriers to Transplantation Tolerance |
| Q35535173 | De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients |
| Q91973783 | Does the Liver Provide Immunosuppressive Advantage? |
| Q35076524 | Effect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients |
| Q47658409 | Evolution of serum and intra-graft donor-specific anti-HLA antibodies in a patient with two consecutive liver transplantations |
| Q46516137 | Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R. |
| Q34041901 | Immunology of naturally transmissible tumours. |
| Q41217333 | Impact of the Trough Level of Calcineurin Inhibitor on the Prevalence of Donor-Specific Human Leukocyte Antigen Antibodies During Long-Term Follow-Up After Pediatric Liver Transplantation: Antibody Strength and Complement-Binding Ability |
| Q90163135 | Influence of Preformed Antibodies in Liver Transplantation |
| Q36007256 | Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians |
| Q35715908 | Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation |
| Q26749457 | Liver transplantation: Current status and challenges |
| Q53187406 | Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays? |
| Q46185349 | Outcomes of Highly Sensitized Patients Undergoing Simultaneous Liver and Kidney Transplantation: A Single-Center Experience With Desensitization |
| Q37623515 | Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients |
| Q91455802 | Pregnancy and donor-specific HLA-antibody-mediated rejection after liver transplantation: "Liaisons dangereuses"? |
| Q40636545 | Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients |
| Q91532589 | Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients |
| Q38757060 | Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice |
| Q89684208 | Rapid reduction of high-level pre-formed donor-specific antibodies after simultaneous liver-kidney transplantation: a report of two cases |
| Q92104125 | Revisiting the liver's role in transplant alloimmunity |
| Q38607546 | Successful long-term outcome of pediatric liver-kidney transplantation: a single-center study. |
| Q26774993 | The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients |
| Q39121357 | The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives. |
| Q38289184 | The clinical relevance of alloantibody in liver transplantation |
| Q44936178 | The imbalance of T helper 17/regulatory T cells and memory B cells during the early post-transplantation period in peripheral blood of living donor liver transplantation recipients under calcineurin inhibitor-based immunosuppression |
| Q93065771 | The impact of alloantibodies directed against the second donor on long-term outcomes of repeat liver transplantation |
| Q35547041 | The role of donor-specific HLA alloantibodies in liver transplantation |
| Q98222297 | Understanding, predicting and achieving liver transplant tolerance: from bench to bedside |
Search more.